KRAS and pancreatic ductal adenocarcinoma: Previously, inhibition of the ATR-CHK1 DDR pathway in expressed pancreatic ductal adenocarcinoma (PDAC) cells resulted in ERK activation, which is a key downstream protein of KRAS [70].